With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Dr. Gabriel Steg introduces a discussion between Drs. Anthony Gershlick and Martial Hamon on achieving a balance between favorable outcomes and reducing bleeding in STEMI patients.
Join Drs. Prystowsky and Wilber as they discuss the results of pivotal cardiac resynchronization therapy trials in heart failure and their potential impact on the current treatment paradigm and guidelines.
Join Drs. Marchlinski, Bax, and Estes for a discussion on recent CRT-D trials, the impact of therapy in early-stage HF patients, and how LVEF, QRS duration, and NYHA class may guide treatment.
Advances have improved the ability to diagnose, prevent, and treat cardiac arrhythmias and associated conditions. Learn about ongoing improvements in arrhythmia management from a stellar Mayo Clinic faculty.
Little success has been realized in achieving target levels for glycemic control, lipids, and blood pressure, as a result the number of patients with diabetes in the U.S. with these risk factors has increased. Drs. Davidson, Blumenthal, and Svec discuss appropriate treatments to guide the physician in the prevention of CVD.
Join Drs. Fonarow, Gold, and Klein as they discuss recent clinical trial data in cardiac resynchronization therapy and left ventricular reverse remodeling in early-stage heart failure patients.
COMPARE, ENDEAVOR IV, SIRTAX-LATE, SPRIT IV -- given the abundance of data comparing the various DES are there any patterns emerging? Dr. King leads a panel discussion with Drs. Cohen and Williams.
Dr. Holmvang presents 2 cases of stent thrombosis to Dr. Kristensen outlining risk factors and potential strategies to prevent this catastrophic event.
Join Drs. Prystowsky and Estes as they discuss risk stratification of patients with hypertrophic cardiomyopathy and strategies for implementing implantable device therapy.
Hypertension affects approximately 73 million adults in the U.S. and is one of the most important risk factors for cardiovascular and renal diseases. Dr. Kountz will focus on current hypertension treatment disparities and high-risk patients while providing a thorough exploration of guideline-based management strategies.
What are the implications of recent data on the antiplatelet agents in ACS for Europe? Recorded at the 2009 ACS Masterclass in Copenhagen, Denmark, Dr. Clemmensen leads a roundtable discussion with Drs. Collet, Kristensen, and Schühlen.
Drs. Izzo and Ruilope discuss the importance of RAS inhibition in controlling hypertension to prevent or delay the development of MA in patients with diabetes.
Join Drs. Alexander, Becker, and Weitz for a discussion on the coagulation cascade, its link to platelet function, and the risk/benefit and clinical utility of agents that target the coagulation cascade and platelet receptors.
Recently reported and new trials of antiplatelet therapy continue to redefine optimal management strategies for patients with atherothrombotic disease and patients with atrial fibrillation. Drs. Harrington, Angiolillo, Bhatt, Connolly, Mehta, and Simon discuss guidelines? recommendations for the use of antiplatelet therapies and the potential impact of emerging data regarding currently used and novel antiplatelet agents.
With the approval of a third-generation thienopyridine, new clinical trial data on novel agents, and the dosing of clopidogrel, Dr. Berger asks Dr. Cohen how he has incorporated this information into his practice.